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APPENDIX I
STRUCTURAL ANALYSIS AS A MEANS OF PREDICTING
CARCINOGENIC POTENTIAL
JOHN ASHBY
If comparison of the molecular structure
of a compound with known carcinogens is
to be used to identify potential carcinogens
and thereby supplement invitroshort-term
tests for potential carcinogenicity (Lewin,
1976; McCann et al., 1975; Duncan,
1975; Purchase et al., 1976; Mayer and
Flamm, 1975; Gadian, 1975), the structure
activity relationships of those known
chemical carcinogens must be considered.
In particular, attention must be given to
which structural features are associated
with carcinogenicity and which structural
changes cannullify that association. In the
discussion which follows, compounds are
classed as carcinogens or non-carcinogens
on the decision ofthose who conducted the
the animal study. The criteria for carcino-
genicity used in the earlier sections of
this paper have not been used here.
Several lists ofspecific chemical carcino-
gens have been drawn up to identify
those chemicals which have been shown
to induce cancer in laboratory animals
(U.S. Public Health Service, 1951; Na-
tional Institute of Occupational Health
and Safety, 1975; Sax, 1975; Howe, 1975;
Hueper, 1955; Munn, 1974; Carter and
Roe, 1975; Rose, 1974; Searle, 1970;
Ferguson, 1975; WHO/IARC, 1972 et seq.)
Several such families of carcinogens have
been identified, for example, the benzi-
dines, aminobiphenyls, polycyclic aromatic
hydrocarbons, aziridines, epoxides etc.
The main drawback to such classifications
is that individual carcinogens are included
without any indication of what effect
simple substitution or minor molecular
change will have upon their carcino-
genicity. In the present circumstances,
where constant reference to a short-term
test is usually possible, the effect of such
changes can be anticipated and evaluated
with these tests.
Such an identification process could be
undertaken via normal molecular modifi-
cation and isosteric substitution, and
should take into account the effects of
probable metabolic transformation. Un-
doubtedly, this approach will sometimes
result in predictions being made which
hitherto would have been considered irra-
tional, but these can now be rapidly eval-
uated and either discarded or developed
further without immediate recourse to con-
ventional long-term animal evaluation.
Existing structure-activity studies of
structural association with carcinogenicity
can also be utilized in this process, but few
generalizations have emerged so far.
Moreover, the structure-activity pattern
observed for one series of carcinogens
does not, in general, apply to other, super-
ficially related series.
This lack of inter-series consistency can
be illustrated by the carcinogenicity of
4-aminobiphenyl (1) (WHO/IARC, 1972)
and the low (Walpole and Williams, 1958)
or non-carcinogenicity (Miller et al., 1956;
Sandin et al., 1952) of its 2-methyl
homologue (2). This loss of activity has
been used to argue in favour of a ring
coplanarity requirement for carcino-
genicity within this series, which the
methyl group disturbs. Further, the car-
cinogenicity of the related, but planar,
2-aminofluorene (3) (Wilson et al., 1941)
supports this concept. Such a steric
constraint might be expected to apply to
the benzidine series of carcinogens, but
2-methylbenzidine (4) is considered a
more potent carcinogen than benzidine
itself (Miller et al., 1956; Arcos and
Arcos, 1974).
A similar situation is encountered when
comparing the effect of ortho-methylation
across several series of aromatic-amine
carcinogens. 3-methyl-2-naphthylamine
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(5) (Griswold et al., 1966) 3-methyl-4-
aminobiphenyl (6) (Walpole and Williams,
1958; Miller, 1962) and ortho-tolidine (7)
(Spitz et al., 1950) each elicit a carcino-
genic effect in laboratory animals equal to
or greater than that observed for their
respective parent compounds, whilst 3-
methyl-4-dimethylaminoazobenzene (8),
the analogous derivative of the carcinogen
4-dimethylaminoazobenzene (DAB), is in-
active (Miller and Miller, 1948, 1953b).
The apparent unpredictability of the
outcomeofisostericmolecularmodification
of known carcinogens is illustrated by
4-acetamidobiphenyl (9) (WHO/IARC,
1972; Walpole and Williams, 1958) and
its methylene-bridged analogue 2-acet-
\ / ~ / NHAc
(9)
NHAc
x
(10) a X = CH2
b X = NH
C X = SO2
amidofluorene (lOa) (Wilson et al., 1941)
both ofwhich are carcinogens. In contrast
2-acetamidocarbazole (lOb), the -NH-
bridged analogue of(lOa)and3-acetamido-
dibenzothiophene-5,5-dioxide (lOc), its
-SO2- bridged analogue, are both non-
carcinogenic (Miller et al., 1955).
Many apparent inconsistencies such as
those outlined above have been partially
explained bythe use ofvarioushypotheses,
but a full understanding of such inter-
and intra-series effects will only follow
from the consideration of metabolic
transformations (Miller and Miller, 1975;
Hathway, 1972, 1975; Vesterberg, 1975),
ultimate carcinogenic form (Miller and
Miller, 1971, 1975; Scribner, 1975), changes
in basicity, acidity partition coefficients,
relative steric effects (Bergman, 1942;
Berenblum, 1974; Bergman and Pullman,
1969; Garner et al., 1975; Holland et al.,
1974) etc. Many series will have to be
restudied in order to obtain this critical
metabolic and chemical information, and
in such cases short-term tests rather than
the original long-term tests can be used to
monitor activity. The rapid progress that
can now be made in structure-activity
studies is illustrated by the marked
carcinogenicity (WHO/IARC, 1972) and
mutagenicity (Garner et al., 1975) of
benzidine ( lla) and the corresponding
inactivity of 3,3',5,5'-tetramethylbenzi-
dine (JIb) both as a carcinogen (Holland
etal., 1974) and as a mutagen (Garner et al.
1975) (S. typhimurium). Furthermore, the
stericallylesshindered3,3',5,5'-tetrafiuoro-
benzine (1 ic) is strongly mutagenic, (Gar-
ner et al., 1975) and will probably there-
\ /N H/ NH2
(1)
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fore prove to be a carcinogen when fully
evaluated.
(11) a X = H
b X = CH3
c X = F
An exhaustive analysis of the available
structure-activity data for most of the
main groups of carcinogens has recently
been undertaken by Arcos and Argus and,
in part, Wolf (Arcos et al., 1968; Arcos
and Argus, 1974). The guiding principle
of their work was to establish or empha-
size order within the field of chemical
carcinogenesis. However, both this and
related studies (Clayson, 1962; Ross,
1962) have failed to establish many
generally applicable structure-activity
principles that are common to the various
series of carcinogens. This is probably
due more to the vagaries of in vivo
testing methods than to the absence of
any underlying coherence between appa-
rently related series of carcinogens. It is
possible that in vitro assays may discern
these underlying patterns which are nega-
ted or at least become obscured in vivo,
especially when results from different
species of test animal or obtained with
different test protocols are compared.
With this in mind, some broad structure-
activity comparisons are outlined below
for the main series ofcarcinogens. Empha-
sis has been placed upon showing the
large range of molecular changes which
can be made to some carcinogens without
loss of their carcinogenic activity. An
attempt has also been made to generate
generalized structures for some of the
classes of carcinogens described and,
when this has not been possible, to indicate
the approximate structural boundaries of
carcinogenicity within these classes. Re-
ferences to relative potency have gener-
ally been avoided. Some of the structural
groupings made below may be questioned
because of differing modes of action or
differing target specificities of chemically
related compounds. This does not, how-
ever, necessarily nullify such a correlation
of chemical similarity. Recently defined
carcinogens of which the basic carcino-
genicity data are still seriously contested
have been omitted from this study, as any
conclusions could prove either premature
or based on controvertible data. None
the less, it is just these areas of concern
that require rapid and well planned
chemical and in vitro evaluation.
Aromatic amines.-The various series of
carcinogenic aromatic amines, viewed
collectively, constitute one of the largest
families of carcinogens. For the present
purpose this grouping is meant to include
the aminobiphenyls, benzidinesandamino-
azobenzenes, the di- and tri(p-amino-
phenyl)methanes, theamninostilbenes,some
amino derivatives of fluorene, dibenzo-
thiophene and dibenzofuran and finally
2-naphthylamine and its analogues. De-
spite the reservations outlined above there
is a growing body of evidence linking
these various series in at least some stages
of their respective carcinogenic processes.
For example, ring hydroxylation and
conjugation is a usual method of detoxifi-
cation and most have been shown to
undergo carcinogenic activation via N-
hydroxylation (Poirier et al., 1967;
Miller et al., 1960, 1961, 1966; Ander-
son et al., 1964; Baldwin and Smith,
1965; Sato et al., 1966; Troll et al.,
1965; Boyland and Manson, 1966). Fur-
thermore, in several series the resultant
N-hydroxy compounds, themselves car-
cinogens, have been shown to undergo
esterification of the N-hydroxy group
followed by reaction with nuclear material,
either purine or protein in origin (Miller
and Miller, 1966; Kriek, 1965; Lin et al.,
al., 1975; Lotlikar et al., 1966). However,
the absence of any reliable rules governing
activity within these series means that
the 4 generic structures (12)-(15) should
be considered as representing them when
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attempting to detect future carcinogens
in this class.
(12)
(13)
N N
x
(14)
(15)
In Structures (12)-(15) the presence of
a second amine substituent should be
considered as optional, thus, Structure
(12) can accommodate both derivatives of
4-aminobiphenyl and benzidine. Similarly,
the point of attachment of the first amine
substituent is not initially critical; for
example, carcinogenicity has been detec-
ted in both 1-amino- and 3-aminofluorene
(U.S. Public Health Service, 1951; Morris
et ali., 1960), both of which are positional
isomers of the parent carcinogen 2-
aminofluorene (14); X CH2. Structure
(13) can accommodate various amino-
stilbene and aminoazobenzene carcino-
gens, and Structure (15) 2-anthramine
(X - Y CH) and analogues such as
2-naphthylamine (X and Y absent). Many
ofthe chemicals included in the structures
(12)-(15) have been prepared and tested,
and many are carcinogenic (Miller and
Miller, 1953 a, b; Miller et al., 1955) when
bearing appropriate, but apparently arbi-
trary, substituents. However, many have
not yet been studied, and their non-
carcinogenicity cannot be assumed. When
considering the nature of the N-sub-
stituents in Compounds (12)-(15) the
complete metabolic equivalence of the fol-
lowing groups should initially be assumed:
NH2, NHCOR, NHOH, NOH(COR),
N(OCOR')(COR), NO, NMe2 and NO2.
There are a few exceptions to the above.
For example, 4-aminoquinoline-1-oxide
(16a) is non-carcinogenic, whilst the cor-
responding 4-nitro- and 4-hydroxylamino
compounds (16b and c) are potent carcino-
gens. However, this is sufficiently rare to
be initially ignored. Disguised forms of
metabolically activatedaminesubstituents
should also be considered as potential
carcinogens. For example, Compound (17)
a cyclic hydroxamic acid prepared from
the carcinogen 4-NQO (16b) (Yaramoi et
al., 1975), possesses the N-hydroxy-N-
acyl grouping found in the ultimate
carcinogenic formof2-acetylaminofluorene
and related carcinogens. Compound (17)
must, therefore, be regarded as a potential
carcinogen worthy of at least in vitro eva-
luation in a short-term test.
HO
N N<wCH3
N N
0 0
(16) a X = NH2 (17)
b X = NO2
c X = N:HOH
A further important generalization of
Structures (12)-(15) can be made in the
light of the established carcinogenicity of
various 2-nitrofuryl compounds (Arcosand
Argus, 1974), an example of which is the
quinazoline (18) (Cohen and Bryan, 1973;
Erturk et al., 1971). The 2-nitrothienyl
analogue (isostere) (19) of (18) has recently
been reported to be carcinogenic whilst
the simple thienyl analogue of(19), where-
inthe-NO2 group is absent, was inactive
(Cohen and Bryan, 1973).
Apart from equating the effect of furan
and thiophene in such situations, the
inactivity of the des-nitro compound
underlines the importance of the nitro
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OH
N~OH
N 02
(18)
(19)
group and, therefore, argues for a connec-
tion between both (18) and (19) and the
4-amino/nitro/biphenyl carcinogens. Thio-
phene andfuran may, therefore, be capable
of acting as direct replacements for a
benzene ring in aromatic-amine carcino-
gens. Recent metabolic studies on com-
pounds such as (18) and (19) also argue in
favour of such a connection (Wang et al.,
1975a). This connection is made even more
viable by the related disclosures that
several heterocyclic compounds, such as
(20) and (21), are potent carcinogens
(Cohen et al., 1975) and mutagens (Wang,
et al., 1975b; Tazima et al., 1975; Olive
and McCalla, 1975).
NO, S /
N NH,
(20)
s
NO, / NHAc
N-N
(21)
Compound (20) represents a single re-
placement and compound (21) a double
replacement of the benzene rings in
benzidine by heteroaromatic rings, each
change occurring with a retention of
carcinogenicity. It would be logical, there-
fore, to generalize Structures (12)-(15)
further to include any heteroaromatic ring
system in place of the benzene rings.
To exemplify the implications of the
above ideas, consider the hypothetical
molecule (22). This compound fits the
generalized formula (14) and should,
therefore, be initially regarded as a
potential carcinogen.
aS>NH_NCOEt
(22)
Despite their apparent generality,
Structures (12)-(15) should not be regar-
ded as exclusive. For example, Com-
pounds (24) (Miller et al., 1955) and (25)
(Cook et al., 1940) can be regarded as
nominal analogues of 2-naphthylamine
(Hueper and Wolfe, 1937) (23) which are
not covered by Structures (12)-(15) and
both are carcinogenic. Further, the ter-
phenyl compound (26) (Miller et al., 1956)
a somewhat distant analogue of 4-amino-
biphenyl, is not covered by the generic
structures, yet is a weak carcinogen.
(23)NH2
(23)
NHAc
(24)
NH2
N s NH2
(25)
\NH,
(26)
Metabolic considerations based on the aryl-
aminecarcinogens.-Metabolic conversions
in this general class of carcinogens have
been studied in greater detail than they
have in any other class. The carcino-
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genic activation mechanism has been
alluded to above. Ring hydroxylation
followed by conjugation is often en-
countered as a metabolic "detoxification"
mechanism in this group of compounds
(Arcos and Argus, 1974). However, it does
not follow from this that the substitution
of a phenolic hydroxyl group in the
nucleus of a known carcinogen will
render it inactive, because, for example,
both 3-hydroxy-4-aminobiphenyl (Gorrod
et al., 1968), and 3,3'-dihydroxybenzidine
(Baker, 1953), are carcinogenic. Despite
these examples, there does exist a general
trend towards non-carcinogenicity when a
carcinogen of this and other classes is
ring-substituted with a polar or lipo-
phobic group, such as hydroxy (OH) or
sulphonic acid group (-SO3H). This is
illustrated by the sulphonic acids (27)
(Spitz et al., 1950) (28) (Rossner, 1937)
(29) (Windaus and Rennhak, 1937) and
(30) (Kinosita, 1937), which are all
non-carcinogenic derivatives of estab-
lished carcinogens. It is possible that 2
separate mechanisms may be operating to
render Compounds (27)-(30) non-carcino-
genic. The first, which would probably
apply to the benzidine derivative (27),
may involve chemical interference with
the metabolic carcinogenic activation of
the -NH2 function by the sulphonic acid
group. Such examples would be expected
to be non-mutagenic in vitro as well as
being non-carcinogenic in vivo. The second
mechanism, which may applytoAnalogues
(28) and (29), may depend upon inter-
ference with the systemic absorption and
distribution of the compound in vivo,
owing to the physical presence of the
polar sulphonic-acid group. Such a mecha-
nism may not automatically interrupt
the expected carcinogenic metabolic acti-
vation of the basic nucleus should it be
allowed to reach the appropriate meta-
bolic site. These compounds may, there-
fore, be mutagenic in vitro yet non-
carcinogenic in vivo. Whilst non-carcino-
genicity is acceptable for a compound,
however it may be arrived at, the above
considerations may lead to someapparent-
ly false predictions of carcinogenic poten-
tial by in vitro tests for some sulphonic-
acid derivatives. It may therefore be
equally as unrealistic to accuse an in vitro
test of producing "false" results in such
cases as it would be to assume that all
compounds containing a sulphonic-acid
group were inherently non-carcinogenic.
HO3S SO3H
H2N NH2
(27)
SO3H /-
CH3
(28)
CSO3H
(29)
HO3S N / N=N N\
(30) CH3
The possibility of in vivo metabolism
of a compound into smaller fragments,
some ofwhich may resemble oractuallybe
carcinogens, is also worth consideration.
A well documented example of this is the
in vivo formation of o-aminoazotoluene
(32) from Scarlet Red (31) (U.S. Public
Health Service, 1951; Stoeber, 1909;
Hayward, 1909).
Compound (32) was subsequently tested
and shown to be a carcinogen, thus ex-
plaining the carcinogenic effect observed
forthe parent dye (31) (U.S. Public Health
Service, 1951; Yoshida, 1932). This
example becomes more important with
the realization that the liver enzyme(s)
"azoreductase", which is held responsible
for the carcinogenic activation of Scarlet
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CH3 CH3 HO
N-/ NNN / NN
(31)
enzymi2/eucti0n
CH3 CH3
e / N=N N/NNH2
(32)
Red, is also responsible for the metabolic
detoxification of other azo carcinogens
such as 4-methylaminoazobenzene (33)
(Kensler, 1949; Rukzki, 1975). The same
enzyme system is, therefore, responsible
for the carcinogenic activation of com-
pound (31) and for the carcinogenic
deactivation of the related compound
(33). This fact alone has serious implica-
tions when testing azo compounds in a
- CH3
N=N N N
H
(33)
test which incorporates metabolic activa-
tion. The microsomal level of the azo-
reductase enzvmes could be critical to
both the test response and its likely in
vivo significance.
Most azo-dyes contain sulphonic-acid
groups. However, before all such com-
pounds are regarded as safe (see above)
attention should be paid to the eventual
position of the sulphonic-acid group after
azoreductase-mediated cleavage of the
compound. For example, cleavage of the
model compound (34) would yield benzi-
dine, and as such may present a potential
source of hazard, whilst the model com-
pound (35) would generate the non-
carcinogenic 3,3'-disulphonic acid deriva-
tive of benzidine.
4-Nitroquinoline-N-oxide (4NQO) (36a).
-This compound and its active analogues
are generally regarded (Arcos and Argus,
1974) as a distinct group of carcinogens,
essentially unrelated to the much larger
class of aromatic amines discussed above.
Although there are some obvious links
with these other carcinogens, such as the
increased carcinogenic activity of the
derived hydroxyamino compound (36b)
(Kawazoe et al., 1967; Paul et al., 1971),
there are good reasons for keeping them
as a separate group. Not least amongst
these reasons is the surprising inactivity
of the corresponding 4-aminoquinoline-N-
oxide (36c) (Kawazoe et al., 1967) when
viewed in the context of other paired
carcinogens such as 4-nitro- and 4-amino-
biphenyl (WHO/IARC, 1972). Further,
susceptibility of the 4-nitro group in
4NQO (36a) to nucleophilic displacement
has added a complication to the study of
metabolic carcinogen activation in this
series not encountered in the others
(Arcos and Argus, 1974)
Two main points of relevance to the
present study emerge from this series.
The first concerns the unusually large
number of changes which can be made to
3H X X
-N=N N\
(34) X = H
(35) X = S03H
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0
(36) a X= NO2
b X = NHOH
c X = NH2
the basic 4NQO structure whilst still
retaining carcinogenic activity. Activity
is retained in 4-chloroquinoline-N-oxide
(Searle, 1965, 1966, 1967, 1968), 4-nitro-
quinoline (Mori et al., 1969), the 6,7
dimethyl analogue (37) (Lacassagne et al.,
1966) and even in quinoline itself (Hirao
et al., 1976). Compound (37) represents a
ring opened form of 6,7-benzo-4-nitro-
quinoline-N-oxide (38) and thus the latter
compound will probably also prove to be
carcinogenic when tested (Arcos and
Argus, 1974) (this structural transition is
well established amongst the polycyclic
aromatic hydrocarbon carcinogens; see
later). Similarly, carcinogenicity is re-
tained with "partial" removal of the
fused benzene ring of 4NQO (34a).
Although the immediately derived 4-nitro-
pyridine-N-oxide is apparently inactive,
its 3-methyl analogue (39) is carcinogenic
(Araki et al., 1971).
NO2 NO2
CH3
CH3 N
0 0
(37) (38)
The second area of interest presented
by the 4NQO series concerns inhibition of
carcinogenicity by steric crowding around
the 4-nitro group. Both 9-nitroacridine-N-
oxide (40) (Hirao etal., 1976) and3-methyl-
4-nitroquinoline-N-oxide (41) are non-
carcinogenic (Kawazoe et al., 1967). In
contrast, the methyl-substituted isomer
(42), where at least one approach to the
nitro group is left unhindered, is carcino-
genic (Kawazoe et al., 1967; Nakahara et
al., 1958). It is possible that interaction of
the 4-nitro group with nitro reductase
N02
(40)
NO2
CH3
0
(41)
0
(42)
enzymes is being sterically inhibited in
compounds (40) and (41), and this is
clearly related to the proposed steric
inhibition of amine-oxidase interaction
(Garner et al., 1975) and established non-
carcinogenicity (Holland et al., 1974) of
3,3',5,5'-tetramethylbenzidine referred to
earlier. Based on the above findings,
Arcos and Argus have predicted (Arcos
and Argus, 1974) that 3,5-dimethyl-4-
nitropyridine-N-oxide (43) will be non-
carcinogenic. Many similar predictions
NO2
(39)
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could be made in superficially related
series, and this steric inhibition of amino
or nitro-mediated carcinogenicity may
well prove to be a general, and extremely
valuable, inter-series effect.
Polycyclic aromatic hydrocarbon8.-So
many compounds in this series are known
carcinogens that any new compound
should undergo some form of evaluation
before being released for widespread use.
Many structure-activity hypotheses have
been advanced to explain carcinogenicity,
or the lack of it, in these compounds
(Arcos et al., 1968; Brookes, 1977; Jerina
and Daly, 1977). Two separate lines of
thought may make these rather obscure
compounds relevant to the large middle
ground of chemicals whose structures do
not directly resemble any of the estab-
lished polycyclic carcinogens. The first of
these concerns the systematic modification
of primary polycylic carcinogens such as
3,4,9,10-dibenzpyrene (44) (U.S. Public
Health Service, 1951). It has been found
that successive replacements of the fused
benzene rings of such compounds with
(44)
CH3
(45)
CH3
CH3
(46)
methyl or alkyl groups often retains
carcinogenicity. In this way the 2
potent carcinogens 3-methylcholanthrene
(45) (U.S. Public Health Service, 1951)
and 7,12-dimethylbenz(a)anthracene (46)
(U.S. Public Health Service, 1951) and the
progressively simpler and weaker carcino-
gens 8,9,10,11-tetrahydro-7,12-dimethyl-
benz(a)anthracene (47) (U.S. PublicHealth
Service, 1951) 1,2,3,4-tetramethylphenan-
threne (48) (Badger et al., 1942) and
9,10-dimethylanthracene (49), (Lijinsky
and Saffiotti, 1965) can be derived.
CH, 7 CH3
< CH3
CHC
CH3 CH3
(47)
CH3
CH3
(49)
CH20H
CH3
(50)
(48)
CH3
CH20H
(51)
Apart from simulating a benzene ring
in the above situations, the methyl groups
themselves may play a part in the carcino-
genic sequence. For example, the hydroxy-
methyl compounds (50) and (51) (Yang
and Dower, 1975), themselves carcinogens
(Boyland, 1969), have been detected as
the major metabolites formed when 7,12-
dimethyl-1,2-benzanthracene (46) is
treated with a liver homogenate from
normal rats. None the less, the production
of these alcohols is probably an artefact
(Brookes, 1977). Whatever their function,
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methyl grouips seemii to be instrumental in
converting the non-carcinogen anthra-
cene into the carcinogen 9,10-dimethyl-
anthracene (49). Correctly positioned
methyl groups, or substituted methyl
groups, must, therefore, be considered
capable of replacing a fused benzene ring
in some carcinogens, and perhaps more
important, be capable of transforming
other non-carcinogenic polycyclic aromatic
compounds into carcinogens (Boyland,
1952). Such an effect can be further
disguised by the appropriate and simul-
tanieous isosteric replacement of a fused
benzene ring by, for example, a thiophene
ring. Many examples of thiophene act-
ing as an equi-active replaeement for a
fused benzene ring have been observed
within this general class of carcinogens
(U.S. Public Health Service, 1951; Sax,
1975). Therefore, bringing both of these
lines together, 3,4-dimethyldibenzothio-
phene (52) (Campaigneetal., 1969a) should
be regarded as a derivative of the weak
carcinogen chrysene (53) (U.S. Public
Health Service, 1951) and as such should
be viewed as potentially carcinogenic and
worthy of in vitro evaluation.
A second area of interest amongst the
polycyclic aromatic carcinogens is that
concerning their putative relationship to
anti-tumour compounds such as ellipticene
(54) and olivacine. The structural simi-
larity of ellipticine to the carcinogen
CH13
N
N
H
CH3
CIA3 -s
CI3
(52) (53)
7,12-dimethylbeuizanthracenie (55) has
been noted elsewhere (Campaigne et al.,
1969b). Furthermore, both of these com-
pounds reduce to even more similar
structures by the isosteric replacement of
the pyrrolic ring of (54) and the "K-ring"
of (55) by thiophene rings giving com-
pounds (56) (Fujiwara et al., 1968) and
(57) (Robinson and Tilak, 1947) respec-
tively. Both ofthese analogues retain their
original properties and both have been
suggested to act via interaction with DNA
base pairs (Boyland, 1969; Swan, 1967).
The above facts taken in the light of
Haddow's paradox (see below) argue for
the inclusion of compounds as remote as
(54) within the present definition of
potential polycyclic carcinogens.
Anti-turnoitr compounds and Haddow's
paradox. Haddow's paradox (Badger et
al., 1942; Haddow, 1947) concerns the
association between anti-tumour (carcino-
lytic) and carcinogenic properties in some
substances. The aspect of particular rele-
(55)
(56)
CH3
(57)
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vance to the presenit study is that a given
anti-tumour compound may under special
circumstances exhibit a carcinogenic effect.
For example, both 4-dimethylaminostil-
bene (Haddow et al., 1948) and 4-nitro-
quinoline-N-oxide (Sakai et al., 1955) were
originally regarded as anti-tumour com-
pounds, and only later, based on Haddow's
paradox, were they tested for carcino-
genicity and found to be active. Likewise
4-chloroquinoline-N-oxide possesses both
carcinolytic and carcinogenic properties
under the appropriate circumstances
(Searle, 1965, 1966, 1967, 1968). There are
areas where the above concept is self
evident, as with the use of alkylating
agents in anti-tumour therapy. For exam-
ple, both cyclophosphamide (Weisburger,
1975) and thioTEPA (U.S. Public Health
Service, 1951) have been shown to
possess carcinogenic properties, and the
nitrosourea anti-tumour agents (Mont-
gomery et al., 1974; Fujiwara et al., 1974)
can be associated with the carcinogenicity
of N-methyl-N-nitrosourea itself. How-
ever, other anti-tumour agents, of which
there are many, are less easily associated
with known carcinogens. Despite the fact
that the basis for labelling these com-
pounds as carcinolytics is often tenuous
it is perhaps worthwhile including them
in a data bank of potential carcinogens for
cross-reference to new compounds being
assessed for potential carcinogenicity.
NAitro8amines, nitro8amides, hydrazines
and azoxyalkyl compounds.-The nitro-
samines, along with a variety of nitro-
CH3\
N-NO
CH3
(58)
0
HN C,NN CONH-
HNN" N NO
(60)
soureas and nitrosoguaniidines, formn a
well established class of carcinogens
(Preussmann et al., 1969; Toth, 1]975;
Magee and Barnes, 1967; Druckrey et al.,
1969; IARC, 1972, 1974; Druckrey, 1975).
The simplest nitrosamines such as di-
methylnitrosamine (58) and nitrosomorph-
oline (59) have been studied in the most
detail; however, relatively exotic nitro-
samines such as nitrosofolic acid (60)
(Wogan et al., 1975), nitrosoephedrine
(Wogan et al., 1975) and the glucitol
derivative (61) (U.S.Public Health Service,
1951) are also animal carcinogens. Nitro-
samines are formed by the reaction of
nitrites with secondary amines over a
range of pH conditions (Ziebarth, 1974;
Challis and Kyrtopoulos, 1976). These
chemical species occasionally occur to-
gether in the environment (IARC, 1972.
1974; Tate and Alexander, 1975; Quarles
and Tennant, 1975; Rao, 1975) and in some
foodstuffs (IARC, 1972, 1974; Shubik,
1975), often under conditions favourable
for nitrosamine formation (Ziebarth, 1974;
Challis and Kyrtopoulos, 1976). The
realization of this fact, and its possible
implications, has led to an increase in the
study of nitrosamines as carcinogens in
laboratory animals and in mutation test
systems. Although a clear link between
occupational or environmental exposure to
nitrosamines and human cancer has not
yet been established, it has been demon-
strated (Bartsche and Montesano, 1975)
that dimethylnitrosamine is activated as
a mutagen by both human and rat liver
D N-I
\(9
(59)
H-
/CH3
CH2N\
NO
OH
HO - H
H -HOH
CO,H
-CH
CO2H
H OH
CH2OH
(61)
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microsomes, and consequently it would be
prudent to regardnitrosamines aspotential
human carcinogens at the present time
(MIontesano, 1975).
The synthesis and properties of the
acetylated ox-hydroxymethylnitrosamine
(62) was recently described (Fahmy et al.,
1975a, b; Wiessler, 1974). This compound
has been shown to possess greater muta-
genic and carcinogenic properties (Fahmy
et al., 1975b) than the parent nitrosamine
(58), and thus its intermediacy in the
metabolic activation of dimethylnitro-
samine as a carcinogen seems likely
(Druckrey, 1975). It must be pointed out
however, that 3-hydroxylation also has
been suggested as a route to the activation
of other analogues such as dibutylnitros-
amine (Althoff et al., 1975). If it is
assumed that ac-hydroxylation is a primary
step in the activation of all nitrosamines
it should follow that analogues having
partially or fully blocked os-positions will
be non-carcinogenic, and this is broadly
observed. Diphenylnitrosamine is non-
carcinogenic in several species (Hashida
et al., 1973; Innes et al., 1969), t-butyl
ethylnitrosamine (63) is both non-carcino-
genic (Druckrey et al., 1963) and non-
mutagenic (Pasternak, 1963) and the
piperidine derivative (64) is of very low or
zero carcinogenicity (Lijinsky and Taylor,
1975) (3-hydroxylation may account for
the residual carcinogenicity).
Two further complicating factors must
be borne in mind when assessing the
carcinogenic risk likely to be associated
AcO-CH2
N-NO
CH3
(62)
Et
N-NO
CH37
CH3 CH3
(63)
NO
with a nitrosamine. The first relates to the
ability of tertiary amines such as (65) to
undergo mono-dealkylation in the presence
of sodium nitrite. The derived secondary
amine can then react further to produce a
nitrosamine (Fiddler et al., 1972). The
second hidden problem centres on the
possibility that non-carcinogenic nitro-
samines such as diphenylnitrosamine may
act as transnitrosating agents to other
secondary amines, thereby producing a
new and potentially carcinogenic nitro-
samine. Transnitrosation is a well estab-
lished phenomenon in aromatic nitrosa-
mines (Buglass et al., 1974; Welzel, 1971)
and in some (Johnston et al., 1975) but not
all (Buglass et al., 1974) aliphatic nitro-
samines. The biological significance of
transnitrosation has been discussed else-
where in the present context (Buglass et
al., 1974; Shapley, 1975), and the recently
established carcinogenicity of nitrosofolic
acid (Wogan et al., 1975) adds weight to
this concern
C"3\ NaV
N\ CO2CH3 NaN'O
CH3
(65)
CH3\
NH
CH3 \NaNO,
CH3\
N-NO
CH3
(58)
The nitrosourea (66) and the nitroso-
guanidine (67) are representatives of the
nitrosamide family of carcinogens (U.S.
Public Health Service, 1951; Druckrey,
1975; Ward and Weisburger, 1975), and
several derivatives are employed as anti-
tumour agents (Wheeler, 1975; Reed and
May, 1975).
Thus, although there is now a much
better understanding of structural re-
quirements for the carcinogenicity of
OyNH2 HNyNHNO2
CH3 NO CH3 NO
(66)
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nitrosamines, all such compounds should
be regarded with caution except in a few
well defined cases such as diphenyl-
nitrosamine. Secondary or tertiary amines
which are likely to come into contact with
nitrites should also be carefully considered.
Two further groups of carcinogens are
worth consideration in the context of
nitrosamine. The first of these is the
azoxylalkane group, ofwhich ethyl azoxy-
ethane (Druckrey et al., 1966) (68) the
cycasin derivative (69) (Matsumoto et al.,
1965; Laqueur, 1964) and perhaps elaio-
mycin (70) (Ehrlich et al., 1954; Schoental,
1967) are representative. It has been
Et-N=N-Et
0
(68)
Et N=N CH2OAc
0
(69)
CH2OC13
C6H3CH CH-NN \ H
Ctlofl
0
CH3
(70)
suggested that the carcinogenicity of both
cycasin and dimethylnitrosamine may be
expressed via a common alkylating inter-
mediate (Miller, 1964; Matsumoto and
Higa, 1966), and this has been made more
likely by the synthesis of the dimethyl-
nitrosamine intermediate (62), which hap-
pens to be isomeric with the cycasin ester
(69). Likewise, a similarity between the
acute liver toxicity produced by both
dimethylnitrosamine and elaiomycin (70)
has been noted (Schoental, 1967). The
second class of compounds which may be
related to the above groups is that of the
hydrazines. Most of the derivatives of
hydrazine which have been tested, in-
cluding derivatives as structurally diverse
as (71) (Toth and Schimizu, 1974), (72)
(Innes et al., 1969), (73) (Toth, 1973) and
hydrazine (Biancifiori and Ribacchi, 1962)
itself, have been proved experimentally to
be carcinogens (Toth, 1975).
In the light of these observations, all
derivatives of hydrazine, excltuding those
-NHNH-C-NH2 HO°X VNHNH2 I INNH
0
(71) (72)
CH3\
/N-NH2
CH3
(73)
in which the hydrazine group forms part of
an aromatic ring system (Colvin, 1969)
(e.g. cinnolines) should be regarded as
potentially carcinogenic (Toth, 1973;
Biancifiori and Ribacchi, 1962). Acid hy-
drazides such as isoniazid (74) have also
been shown to be experimental carcino-
gens (Biancifiori and Ribacchi, 1962;
Mori et al., 1960; Miller, 1975;) although
the effect in such compounds is probably
mediated via metabolic transformation to
hydrazine (Colvin, 1969).
CONHNH2
in vitro I N NO/ N-NH2
(74) (59) (75)
The reason for including hydrazine
derivatives in the present group stems
from the suggestion of Preussmann et
al. (1969) that metabolic oxidation
of hydrazines to azo or azoxy com-
pounds may precede their carcinogenic
response. Further, nitrosomorpholine (59)
is reduced in vitro by guinea-pig liver
microsomes to N-aminomorpholine (75)
(Suss, 1965), a derivative of hydrazine.
The weak mutagenicity of (75) (Suss, 1965)
and the mutagenicity (Lingens, 1964) and
carcinogenicity (Toth, 1973) of the closely
related 1,1-dimethylhydrazine (73) led to
the suggestion that intermediate hydrazine
formation was a possible step in the
carcinogenic activation of nitrosamines in
general (Suss, 1965). However, the oxida-
tive route of activation of hydrazine
derivatives is currently the most favouired.
Alkylating agents
Several grouips of carcinogens elicit
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their effects via the metabolic formation of
alkylating species (e.g. the nitrosamines
and alkylhydrazines). However, a large
number of compounds can be grouped
under the general heading of alkylating
agents. In its simplest and chemical
sense this definition is meant to include
compounds which are capable of reacting
with nucleophiles. However, the aspect of
relevance to the present analysis iswhether
such compounds are capable of acting as
biologically significant alkylating agents,
a distinction not always immediately
apparent. Examples of most of the chemi-
cal types included within this group can be
found among the alkylating agents used in
anti-tumour therapy, e.g. (76)-(79). These
examples happen to be bifunctional, and
most are known to react with nuclear DNA
(Ross, 1962). In theory, at least, any
compound which possesses a chemical
leaving group that can irreversibly inter-
act with a nucleophile has carcinogenic
potential. However, experience has modi-
fied this position to the point that carcino-
genicity is usually only associated with
discrete and optimally activated members
of a particular class (Ross, 1962). For
example, the alkylating activity of the
carcinogen f-propiolactone (80) (Roe and
Salaman, 1955) appears to be strongly
dependent upon the ring strain present in
this compound, because in the less
strained homologue, y-butyrolactone (81)
(Dickens and Jones, 1961) carcinogenicity
is absent. Lactones, in fact, form a com-
paratively small group of carcinogens
wherein the structural requirements for
carcinogenic activity are partially under-
stood (Dickens, 1964). Activity is most
generally associated with unsaturated
lactones such as patulin (82) (Dickens.
1964) and aflatoxin B1 (83) (U.S. Public
Health Service, 1951) where the carcino-
genic action is probably not totally
dependent upon the lactone ring. The
chemical alkylating agents form too large
a group of compounds for any general
stance to be adopted when predicting
carcinog,enicity for a new member, and the
situatioiri will not be helped bv the possi-
H /CH2CH2C1
KI<>CH\CH2CH2C1
(76)
CH3SO2-0 OSO2CH3
(77)
'~7
N
II CN P NJ
s
(78)
0 0-[CH2CH20J13
CH -CH CH-CH2
0 0
(79)
0
0
AO 0°
(80) (81)
0
0
0
H
OCH3
(83)
H
0 OH
(82)
bility that in vitro tests might find all
such compounds positive. The partition
coefficient, chemical half-life and specific
nucleophile reactivity of each possible
carcinogen of this class will probably
determine whether any carcinogenic effects
are observed in animals.
Mliscellaneous groups
Several apparently miscellaneous carci-
nogens can be grouped togQther because
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each possesses an activated carbon-
carbon double bond which is known to
react with biologically occurring nucleo-
philes. This type of reaction is usually
detected by the isolation of cysteine or
methionine adducts, the carcinogenic sig-
nificance of which is uncertain. Such a
reaction may only represent a common
detoxification pathway, but it could also
be taken as an indicator of the established
carcinogenicity ofthese compounds, which
is usually mediated via a derived epoxide.
Obviously not all compounds that react
with biologically occurring sulphur com-
pounds are carcinogens (Harington, 1967)
but some predictive significance may be
attached to the following examples. Areco-
dine (84) is the suggested carcinogenic
principle of betel nuts, and in the rat it is
converted to the cysteine adduct (85),
amongst other metabolites (Boyland and
Nery, 1969; Nery, 1971).
H
(84)
zH
H2C=C\..
(86)
NHAc
N3 <H S-CH-C02H
k C02H
N
CH3
(85)
H2N-CH-CH2-S >C
CO2H
(87)
Similarly, the cysteine adduct (87) has
been isolated from the urine of rats dosed
with the carcinogen vinyl chloride (86)
(Green and Hathway, 1975). Safrole (88)
(Innes et al., 1969), and its synthetic
metabolite acetoxysafrole (89) (Borchert
et al., 1973) are both carcinogenic, and
likewise the latter compound has been
shown to react with methionine via
addition to the double bond and replace-
ment ofacetate ion, to give the thiomethyl
adduct (90) (Borchert et al., 1973).
Interestingly, this same derivative (89)
(88)
0b 0
Methionine
AcO-C-CH-CH CHCCH-CH,SCH,
(90) H 0
(89)
was also shown to react with guanosine
monophosphate to produce the analogous
0-6 alkylation product, (Borchert et al.,
1973) thus paralleling a biologically
important reaction with the methionine
"marker reaction". A similar arrangement
of atoms to that found in (89) (allylic
leavinggroup)ispresentinthepyrrolizidine
alkaloid carcinogens such as heliotrine (91)
(Schoental, 1975), although at least 2
alternative mechanisms of carcinogenic
action have been proposed for these
compounds (Mattocks, 1974; Culvenor et
al., 1976). Several classes of anti-tumour
agents also fall into this general classifica-
tion of activated double bonds, e.g. the
chalcones oftype(92)(Dore andViel, 1974).
- ~OH HO 0 H
I, I CH3
NH H'/CH3 H\
3 CH
(91)
0
H
R'
(92)
918SIX TESTS FOR CARCINOGENICITY
However, although Michael acceptors
appear to offer a potential alkylation site,
and therefore could be classed as potential
carcinogens, the following is pertinent.
The keto-derivative of safrole (93) reacts
readily but reversibly with DNA anditwas
non-carcinogenic when tested alongside
compounds (88) and (89) (Wislocki, 1974).
0
0
o \
(93)
None the less, acrylonitrile, which is an
efficient Michael acceptor has been shown
to be carcinogenic (British Industrial
Biological Research Association, 1977). In
this case it is probable that intermediate
formation of a derived epoxide had medi-
ated the observed carcinogenic effect.
Potential carcinogenicity was predicted
for this compound by an in vitro test long
before animal carcinogenicity was defined
(Venitt et al., 1977).
General considerations
The metabolic conversion of a chemical
to an active intermediate capable of
reacting with DNA will usually be a
dynamic and competitive process. Whilst
one metabolic sequence may activate a
compound, there will usually be several
alternative transformations operating at
the same time which will deactivate either
the test chemical or any derived active
intermediates. Therefore, whether or not
a signifcant DNA reactivity is obtained
for a compound, either in vitro or in vivo,
may depend upon the net balance between
activation and deactivation pathways for
the compound in a given metabolic
situation. The possibility exists, therefore,
that structural and metabolic considera-
tions may suggest that a compound will
possess DNA reactivity and is therefore a
60
potential carcinogen, yet due to the
unforeseen dominance of certain deactiva-
tion pathways it may be inactive both in
vitro and in vivo. In other words, many
compounds may be classed as potential
carcinogens by virtue of the postulated or
established existence of an activation
pathway in their metabolism, yet only
those with a significant activation compo-
nent to their overall metabolism will prove
active.
The above considerations will lead to
structural analysis over-estimating the
number of potential carcinogens within a
group of compounds. In contrast, the
suppression of metabolic deactivation
pathways with appropriate competitive
substrates could lead to the accentuation
of an otherwise minor activation pathway
for a compound, as evidenced by a
negative in vitro test response, and the
production of a positive response. How-
ever, to contrive a positive test response
for an otherwise inactive compound would
be to justify the initial structural concerns
at the expense of ignoring the metabolic
reality for the compound.
If structural analysis is to be employed
as a method of predicting carcinogenicity,
the above uncertainties must be clearly
recognized. For example, it would be
justifiable to be suspicious, initially, of all
aromatic nitro compounds because each
may undergo metabolic transformation to
aDNA-reactive hydroxylamine-esterinter-
mediate. However, only those nitro com-
pounds which form a biologically signifi-
cant level of such an intermediate,
probably as evidenced by a positive in
vitro test response, should be considered
as potentially carcinogenic. It therefore
follows that a negative in vitro response
given by structurally suspect compounds
will often represent a failure to anticipate
correctly the overall metabolism of a
compound, rather than a failure of struc-
tural analysis per se. The obvious sensiti-
vity of this approach means that its best
place in any screening battery is at the
beginning, and that it should be applied
even before in vitro testing is initiated.
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Concluding comments
The past few years have witnessed an
unprecedented increase both inthenumber
of newly defined carcinogens and in our
general awareness of the potential hazard
to humans which carcinogens in general
may pose. During thisperiod avarietyofin
vitro tests have become generally accepted
as being useful contributors to any
attempts to detect carcinogens, and a
large number of long-term carcinogenicity
studies have been either initiated or
completed. Moreover, these studies have
indicated that carcinogenicity may not be
the rare and structurally confined pheno-
menon it was once thought to be. If this
trend continues, or increases, a situation
will arise wherein a bewilderingly diverse
collection of organic chemicals will be
defined as carcinogens for at least one
species ofanimal, a condition which will be
exacerbated by a mounting backlog of
potential animal carcinogens as defined
by in vitro assays.
In contrast, if an attempt is made to
define areas of maximum potential hazard
(via structural considerations and human-
exposure estimations) and to study these
areas in coordinated programmes, a much
greater impact on the hypothetical human
problem (Higginson, 1969) could be made.
It has been suggested that the current
lack of a sufficient data-base substantially
limits the use of structural analysis in
predicting carcinogenicity (Fisher and
Fishbein, 1977). This, however, merely
emphasizes the points made above. That
carcinogenesis and mutagenesis are not
completely arbitrary and unpredictable
phenomena has been amply demonstrated
already; what is lacking is a current
willingness to plan future testing in such a
way as to generate a sound data-base for
future predictions. If this is not under-
taken, the situation will develop wherein
responsible agencies are forced to react
individually to each alert without taking
cognizance of structurally related com-
pounds which may also present a potential
hazard, or of these newly defined animal
carcinogens, which is likely to present a
real human hazard. This could lead to a
clogging of the very machinery which has
been instituted to protect people.
Attempts to devise testing priorities
and either discern or generate structure-
activity relationships, with anaccompany-
ing chemical rationale for the observed in
vivo or in vitro effects which may be
associated with a new carcinogen, might
enable the current flood of data to be
transformed into an ordered attack on the
proposed problem.
None the less, it would be misleading to
infer that all compounds capable of
inducing tumours in animals can be so
rationalized and classified. None of the
chemical considerations referred to above
can explain how, for example, saccharin
or phenobarbitone induce tumours in
animals, neither do in vitro tests find such
compounds positive. If such compounds
were to be increasingly detected, and if
the biological effects they elicit should be
considered significant to man, a new and
diffuse class ofpotential carcinogens would
have to be recognized, a class not open to
the above methods of prediction (Ashby
et al., 1978).
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